HRP20150058T1 - Imunogeni spojevi koji sadrže hiv gp41 peptid vezan na protein nosaäś crm197 - Google Patents
Imunogeni spojevi koji sadrže hiv gp41 peptid vezan na protein nosaäś crm197 Download PDFInfo
- Publication number
- HRP20150058T1 HRP20150058T1 HRP20150058AT HRP20150058T HRP20150058T1 HR P20150058 T1 HRP20150058 T1 HR P20150058T1 HR P20150058A T HRP20150058A T HR P20150058AT HR P20150058 T HRP20150058 T HR P20150058T HR P20150058 T1 HRP20150058 T1 HR P20150058T1
- Authority
- HR
- Croatia
- Prior art keywords
- immunogenic compound
- compound according
- preparation
- preparation according
- vib
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 12
- 230000002163 immunogen Effects 0.000 title claims 11
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 title claims 5
- 102000014914 Carrier Proteins Human genes 0.000 title claims 2
- 108010078791 Carrier Proteins Proteins 0.000 title claims 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 3
- 239000001488 sodium phosphate Substances 0.000 claims 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000001571 immunoadjuvant effect Effects 0.000 claims 2
- 239000000568 immunological adjuvant Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- FVVLNTONACGHGU-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoic acid Chemical compound C1=CC(CCCC(=O)O)=CC=C1N1C(=O)C=CC1=O FVVLNTONACGHGU-UHFFFAOYSA-N 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Imunogeni spoj koji sadrži peptid odabran iz skupine koja se sastoji od slijedećih formula (VIa) i (VIb):
NH2-(A1)m-SEQ IDN°2-(A2)n-COOH (VIa),
NH2-(A1)m-SEQ IDN°6-(A2)n-COOH (VIb),
naznačen time da:
- m je cijeli broj koji predstavlja 0 ili 1,
- n je cijeli broj koji predstavlja 0 ili 1,
- A1 je aminokiselinski ostatak, i
- A2 je aminokiselinski ostatak,
te je peptid s formulom (VIa) ili (VIb) kovalentno vezan na protein nosač koji sadrži CRM197 protein.
2. Imunogeni spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koja se sastoji od SEQ ID N°5 i SEQ ID N° 7.
3. Imunogeni spoj prema bilo kojem zahtjevu 1 do 2, naznačen time da je kovalentno vezan na CRM197 protein preko njegovog aminokiselinskog ostatka na N-terminalnom kraju.
4. Imunogeni spoj prema bilo kojem zahtjevu 1 do 3, naznačen time da je kovalentno vezan na CRM197 protein preko skupine premosnice.
5. Imunogeni spoj prema zahtjevu 4, naznačen time da navedena skupina premosnice je produkt reakcije sredstva premosnice koje ima dvije reaktivne skupine s oba CRM197 i peptidom s formulom (VIa) ili (VIb).
6. Imunogeni spoj prema zahtjevu 5, naznačen time da navedena skupina premosnice sadrži sukcimidil 4-[p-maleimidofenil]butirat (SMPB) i sulfo-SMPB.
7. Pripravak naznačen time da sadrži imunogeni spoj prema bilo kojem zahtjevu od 1 do 6 u kombinaciji s jednom ili više imunoadjuvantnih supstanci.
8. Pripravak prema zahtjevu 7, naznačen time da je prilagođen da tvori pripravak cjepiva koji je spreman za korištenje koji sadrži količinu navedenog imunogenog spoja u rasponu od 0.01 µg do 200 µg po jedinici doziranja izraženo kao ekvivalent antigenog peptida, poželjno od 0.05 µg do 50 µg po jedinici doziranja, te najpoželjnije od 0,1µg do 20 µg po jedinici doziranja.
9. Pripravak prema bilo kojem zahtjevu 7 i 8, naznačen time da navedena imunoadjuvantna supstanca sadrži aluminijev hidroksid (Al(OH)3).
10. Pripravak prema zahtjevu 9, naznačen time da je prilagođen da tvori pripravak cjepiva koji je spreman za korištenje koji sadrži konačnu koncentraciju aluminijevog hidroksida u rasponu od 0.1 mg/mL do 5 mg/mL, poželjno od 0.05 mg/mL do 2 mg/mL, te je najpoželjnije od 1 mg/mL, izraženo kao sadržaj Al3+ iona.
11. Pripravak prema bilo kojem zahtjevu 8 do 10, naznačen time da je prilagođen da tvori pripravak cjepiva koji je spreman za korištenje koji sadrži konačnu koncentraciju od 0.1 mM do 50 mM natrijevog fosfata, poželjno 0.5 mM do 15 mM natrijevog fosfata, te najpoželjnije 1 mM natrijevog fosfata.
12. Pripravak prema bilo kojem zahtjevu 8 do 11, naznačen time da je u tekućem obliku ili u krutom obliku, uključujući liofilizirani oblik.
13. Pripravak cjepiva naznačen time da sadrži imunogeni spoj prema bilo kojem zahtjevu 1 do 6, ili pripravak prema bilo kojem zahtjevu 7 do 12, s jednim ili više farmaceutski prihvatljivih nosača.
14. Spoj prema bilo kojem zahtjevu od 1 do 6, ili pripravak prema bilo kojem zahtjevu 7 do 12, ili pripravak cjepiva prema zahtjevu 13, naznačen time da je za uporabu kao lijek.
15. Imunogeni spoj prema bilo kojem zahtjevu 1 do 6, ili pripravak prema bilo kojem zahtjevu 7 do 12, ili pripravak cjepiva prema zahtjevu 13, naznačen time da je za uporabu za sprječavanje i/ili liječenje stanja koje je uzrokovano infekcijom pojedinca sa HIV virusom.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305602.0A EP2668959B1 (en) | 2012-05-31 | 2012-05-31 | Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150058T1 true HRP20150058T1 (hr) | 2015-04-10 |
Family
ID=48793339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150058AT HRP20150058T1 (hr) | 2012-05-31 | 2015-01-16 | Imunogeni spojevi koji sadrže hiv gp41 peptid vezan na protein nosaäś crm197 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9511136B2 (hr) |
| EP (2) | EP2668959B1 (hr) |
| JP (1) | JP6352251B2 (hr) |
| KR (1) | KR102077876B1 (hr) |
| CN (1) | CN104507496B (hr) |
| AU (1) | AU2013269120B2 (hr) |
| BR (1) | BR112014029861B1 (hr) |
| CA (1) | CA2875162C (hr) |
| DK (1) | DK2668959T3 (hr) |
| EA (1) | EA027803B1 (hr) |
| ES (2) | ES2528109T3 (hr) |
| HR (1) | HRP20150058T1 (hr) |
| IN (1) | IN2014DN10128A (hr) |
| MX (1) | MX360206B (hr) |
| PL (1) | PL2668959T3 (hr) |
| PT (1) | PT2668959E (hr) |
| RS (1) | RS53769B1 (hr) |
| SI (1) | SI2668959T1 (hr) |
| UA (1) | UA118542C2 (hr) |
| WO (1) | WO2013179262A1 (hr) |
| ZA (1) | ZA201409023B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140335119A1 (en) * | 2004-02-06 | 2014-11-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL |
| RS63080B1 (sr) * | 2015-04-17 | 2022-04-29 | Biolife Science Qld Ltd | Kompozicija vakcine i njene upotrebe |
| WO2016184973A1 (en) * | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184963A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184962A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| EP3574915A1 (en) * | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| EP4115900A1 (en) * | 2021-07-05 | 2023-01-11 | Diaccurate | Novel antigens and vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1445614A1 (en) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method for the in vitro assessment of the progression status of an HIV virus in an invidual |
| PL2336147T3 (pl) * | 2003-12-17 | 2015-01-30 | Janssen Alzheimer Immunotherap | Immunogenne koniugaty A beta z nośnikiem peptydowym i sposoby ich otrzymywania |
| WO2010022740A2 (en) * | 2008-08-28 | 2010-03-04 | Aarhus Universitet | Hiv-1 envelope polypeptides for hiv vaccine |
| US7965010B2 (en) * | 2008-09-03 | 2011-06-21 | Bose Corporation | Linear motor with patterned magnet arrays |
| WO2010040853A1 (en) * | 2008-10-10 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method |
-
2012
- 2012-05-31 PT PT123056020T patent/PT2668959E/pt unknown
- 2012-05-31 EP EP12305602.0A patent/EP2668959B1/en active Active
- 2012-05-31 RS RS20150035A patent/RS53769B1/en unknown
- 2012-05-31 SI SI201230130T patent/SI2668959T1/sl unknown
- 2012-05-31 DK DK12305602.0T patent/DK2668959T3/en active
- 2012-05-31 PL PL12305602T patent/PL2668959T3/pl unknown
- 2012-05-31 ES ES12305602.0T patent/ES2528109T3/es active Active
-
2013
- 2013-05-30 ES ES13737420T patent/ES2701084T3/es active Active
- 2013-05-30 EA EA201491969A patent/EA027803B1/ru not_active IP Right Cessation
- 2013-05-30 CN CN201380041048.0A patent/CN104507496B/zh active Active
- 2013-05-30 US US14/404,254 patent/US9511136B2/en active Active
- 2013-05-30 MX MX2014014526A patent/MX360206B/es active IP Right Grant
- 2013-05-30 IN IN10128DEN2014 patent/IN2014DN10128A/en unknown
- 2013-05-30 CA CA2875162A patent/CA2875162C/en active Active
- 2013-05-30 AU AU2013269120A patent/AU2013269120B2/en active Active
- 2013-05-30 KR KR1020147036531A patent/KR102077876B1/ko active IP Right Grant
- 2013-05-30 EP EP13737420.3A patent/EP2854846B1/en active Active
- 2013-05-30 JP JP2015514666A patent/JP6352251B2/ja active Active
- 2013-05-30 UA UAA201412809A patent/UA118542C2/uk unknown
- 2013-05-30 WO PCT/IB2013/054482 patent/WO2013179262A1/en active Application Filing
- 2013-05-30 BR BR112014029861-0A patent/BR112014029861B1/pt active IP Right Grant
-
2014
- 2014-12-09 ZA ZA2014/09023A patent/ZA201409023B/en unknown
-
2015
- 2015-01-16 HR HRP20150058AT patent/HRP20150058T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150032266A (ko) | 2015-03-25 |
| WO2013179262A1 (en) | 2013-12-05 |
| ES2528109T3 (es) | 2015-02-04 |
| US9511136B2 (en) | 2016-12-06 |
| IN2014DN10128A (hr) | 2015-08-21 |
| CA2875162C (en) | 2021-09-14 |
| KR102077876B1 (ko) | 2020-02-14 |
| EA027803B1 (ru) | 2017-09-29 |
| BR112014029861B1 (pt) | 2022-05-24 |
| EP2668959B1 (en) | 2014-11-05 |
| EP2668959A1 (en) | 2013-12-04 |
| SI2668959T1 (sl) | 2015-03-31 |
| EP2854846B1 (en) | 2018-09-12 |
| RS53769B1 (en) | 2015-06-30 |
| MX2014014526A (es) | 2015-06-02 |
| AU2013269120B2 (en) | 2017-04-20 |
| CN104507496B (zh) | 2018-08-03 |
| DK2668959T3 (en) | 2015-01-26 |
| AU2013269120A1 (en) | 2014-12-18 |
| PL2668959T3 (pl) | 2015-04-30 |
| US20150147348A1 (en) | 2015-05-28 |
| PT2668959E (pt) | 2015-02-05 |
| CA2875162A1 (en) | 2013-12-05 |
| JP6352251B2 (ja) | 2018-07-04 |
| JP2015519359A (ja) | 2015-07-09 |
| ZA201409023B (en) | 2016-08-31 |
| EA201491969A1 (ru) | 2015-04-30 |
| MX360206B (es) | 2018-10-24 |
| ES2701084T3 (es) | 2019-02-20 |
| EP2854846A1 (en) | 2015-04-08 |
| BR112014029861A2 (pt) | 2017-07-25 |
| CN104507496A (zh) | 2015-04-08 |
| UA118542C2 (uk) | 2019-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150058T1 (hr) | Imunogeni spojevi koji sadrže hiv gp41 peptid vezan na protein nosaäś crm197 | |
| HRP20161280T1 (hr) | Farmaceutski pripravci | |
| JP2015519359A5 (hr) | ||
| ES2731899T3 (es) | Composición de vacuna nasal contra la gripe | |
| HRP20191843T1 (hr) | Mikobakterijski antigenski pripravak | |
| HRP20170433T1 (hr) | Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci | |
| MX2013005478A (es) | Compuestos heterociclicos condensados antivirales. | |
| AR110986A2 (es) | Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso | |
| PE20121517A1 (es) | Compuestos lipopeptidos y metodos relacionados | |
| HRP20170421T1 (hr) | Inhibitori replikacije virusa gripe | |
| IL207468A (en) | HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections | |
| BRPI0907087A2 (pt) | ácidos nucleicos de fórmula (i) (nuglxmgnnv)a e derivados dos mesmos como um agente imunoestimulante/adjuvante | |
| HK1156847A1 (en) | Pharmaceutical formulations and methods for treating respiratory tract infections | |
| RU2015106791A (ru) | Иммуногенные композиции | |
| EP2341931A1 (en) | Vaccine composition for use against influenza | |
| CO6761399A2 (es) | Composiciones y métodos de vacuna del virus tipo 1b de diarrea viral bovina | |
| AU2015211356B2 (en) | Combination product for the prevention of sexually transmitted infections | |
| WO2019118393A1 (en) | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration | |
| HRP20140590T1 (hr) | Tekuä†i oblik g-csf konjugata | |
| BR112012003907A2 (pt) | composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês | |
| Patil et al. | Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration | |
| Saadh et al. | Silver nanoparticles with epigallocatechingallate and zinc sulphate significantly inhibits avian influenza A virus H9N2 | |
| BR112012013199A8 (pt) | Composto, composição farmacêutica, e , uso de um composto | |
| JP2016534062A5 (hr) | ||
| IL303225A (en) | Reducing viral infections |